Early detection of endometrial cancer by examining methylation of tumor suppressor genes RASSF1A and RASSF2A in Iranian Endometrial Carcinoma Patients

The endometrial cancer (EC) is the seventh most common malignancies worldwide among female, and it has been shown to be a complex disease driven by abnormal genetic and epigenetic alterations, as well as environmental factors. Aberrant DNA methylation is best an epigenetic event in humans is associated with many human tumors. Including CPG island methylation that play a critical role in the control of gene expression. In the present study, we investigated the methylation pattern in promoter region of RASSF1A and RASSF2A genes in endometrial cancer patients in Iranian women, to compare correlations between Tissue and blood samples and clino pathological parameters. Blood and (n = 26) and formalin fixed paraffin embedded (FFPE) samples (n=28) were collected from endometrial cancer patients. Isolation of genomic DNA from FFPE and peripheral blood was performed and Methylation-Specific PCR (MSP) was applied for analysis the promoter CpG methylation status of RASSF1A and RASSF2A genes in the studied population. Methylation status between tissue and blood samples of RASSF1A, and RASSF2A genes was not significant (p=0.49 and 0.09 respectively). Our results indicated Correlation between ages, menosososal state, myometrial invasion and tumor grade with RASSF1A, and RASSF2A promoter methylation. In our study methylation of both RASSF1A and RASSF2A genes is an important event in carcinogenesis of endometrial cancer. Epigenetic alternations may have important role for early diagnosis and can be a molecular target for treatment. The results of this research could be useful for genetic counseling for cancer treatment max system.